How is Lassa fever treated?
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Treatment of Lassa Fever: Current Approaches and Emerging Therapies
Ribavirin as the Standard Treatment
Intravenous Ribavirin for Acute Infection
Ribavirin is the most commonly recommended treatment for Lassa fever, endorsed by both national and international health guidelines. Intravenous (IV) ribavirin is particularly effective when administered early in the course of the infection. Studies have shown that early administration of IV ribavirin significantly reduces mortality rates in patients with high-risk factors such as elevated aspartate aminotransferase (AST) levels and high viremia . However, the evidence supporting ribavirin's efficacy is primarily based on a single clinical trial with a critical risk of bias, necessitating further research to validate these findings.
Post-Exposure Prophylaxis with Oral Ribavirin
For individuals who have been exposed to the Lassa virus but are not yet symptomatic, oral ribavirin is recommended as a post-exposure prophylactic measure. This approach aims to prevent the onset of the disease and reduce the risk of severe outcomes.
Combination Therapies
Ribavirin and Immune Plasma
Combining ribavirin with immune plasma has shown promising results in animal models. In a study involving Lassa virus-infected cynomolgus monkeys, the combination treatment significantly improved survival rates compared to either treatment alone, especially when administered later in the infection course. This suggests that combination therapies could be more effective in treating advanced cases of Lassa fever.
Ribavirin and Dexamethasone
In some cases, adjunctive treatment with dexamethasone, an anti-inflammatory agent, has been used alongside ribavirin to manage hyperinflammation and concomitant infections. This combination has been reported to successfully treat complicated cases of Lassa fever, although more research is needed to establish its efficacy.
Ribavirin and Favipiravir
A novel approach involves the use of ribavirin in combination with favipiravir, another antiviral drug. This combination has been used in human cases with some success, although it was associated with side effects such as transaminitis and prolonged viral RNA presence in blood and semen, raising concerns about potential sexual transmission of the virus.
Emerging Therapeutic Options
Favipiravir
Favipiravir has shown efficacy in preclinical studies involving rodent and non-human primate models. In macaques, a high-dose regimen of favipiravir successfully treated Lassa virus infection, indicating its potential as a viable treatment option for humans .
Human Monoclonal Antibody Cocktail
Another promising treatment in the development pipeline is a human monoclonal antibody cocktail. This therapeutic approach has demonstrated efficacy in preclinical models and holds potential for future clinical application.
Conclusion
While ribavirin remains the cornerstone of Lassa fever treatment, its efficacy is primarily supported by limited and potentially biased clinical data. Combination therapies involving ribavirin and other agents like immune plasma, dexamethasone, and favipiravir show promise and may offer more effective treatment options. Emerging therapies, including favipiravir and monoclonal antibody cocktails, are also under investigation and could provide new avenues for managing this neglected tropical disease. Further research and clinical trials are essential to validate these treatments and improve outcomes for Lassa fever patients.
Sources and full results
Most relevant research papers on this topic